tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

ATHE Stock Latest News

Alterity Therapeutics completes last patient visit in ATH434-202 Phase 2 trial
The FlyAlterity Therapeutics completes last patient visit in ATH434-202 Phase 2 trial
11d ago
ATHE
Alterity Therapeutics Completes Key Phase 2 Trial for MSA Treatment
PremiumCompany Announcements
Alterity Therapeutics Completes Key Phase 2 Trial for MSA Treatment
11d ago
6K
ATHE
Alterity Therapeutics Reports Progress and Financial Results
PremiumCompany Announcements
Alterity Therapeutics Reports Progress and Financial Results
28d ago
ATHE
Buy Rating for Alterity Therapeutics: Strong Financial Position and Promising Clinical Results
PremiumRatings
Buy Rating for Alterity Therapeutics: Strong Financial Position and Promising Clinical Results
1M ago
ATHE
Alterity Therapeutics Announces Change in Substantial Holding
PremiumCompany Announcements
Alterity Therapeutics Announces Change in Substantial Holding
2M ago
6K
ATHE
Alterity Therapeutics Expands Capital with New Securities Quotation
PremiumCompany AnnouncementsAlterity Therapeutics Expands Capital with New Securities Quotation
2M ago
6K
ATHE
Alterity Therapeutics Issues Over 1 Billion New Shares
Premium
Company Announcements
Alterity Therapeutics Issues Over 1 Billion New Shares
2M ago
6K
ATHE
Alterity Therapeutics raises A$40M in placement
Premium
The Fly
Alterity Therapeutics raises A$40M in placement
2M ago
ATHE
Alterity Therapeutics Ltd (ADR) trading halted, news pending
PremiumThe Fly
Alterity Therapeutics Ltd (ADR) trading halted, news pending
2M ago
ATHE
Alterity Therapeutics downgraded to Hold from Speculative Buy at Benchmark
PremiumThe Fly
Alterity Therapeutics downgraded to Hold from Speculative Buy at Benchmark
2M ago
ATHE
Alterity Therapeutics price target raised to $12 from $8 at Maxim
PremiumThe Fly
Alterity Therapeutics price target raised to $12 from $8 at Maxim
2M ago
ATHE
Alterity Therapeutics announces ATH434 Phase 2 trial results
PremiumThe Fly
Alterity Therapeutics announces ATH434 Phase 2 trial results
2M ago
ATHE
Alterity Therapeutics Ltd (ADR) trading halted, news pending
PremiumThe FlyAlterity Therapeutics Ltd (ADR) trading halted, news pending
2M ago
ATHE
Alterity Therapeutics reports cash balance of A$4.54M as of December 31
Premium
The Fly
Alterity Therapeutics reports cash balance of A$4.54M as of December 31
2M ago
ATHE
Alterity Therapeutics Expands ASX Quoted Securities
Premium
Company Announcements
Alterity Therapeutics Expands ASX Quoted Securities
2M ago
6K
ATHE
Alterity Therapeutics Reports Key Advances and Anticipates Milestones in 2025
PremiumCompany Announcements
Alterity Therapeutics Reports Key Advances and Anticipates Milestones in 2025
3M ago
6K
ATHE
Alterity CEO says ‘filled with optimism for 2025’
PremiumThe Fly
Alterity CEO says ‘filled with optimism for 2025’
3M ago
ATHE
Alterity Therapeutics initiated with a Buy at Maxim
PremiumThe Fly
Alterity Therapeutics initiated with a Buy at Maxim
4M ago
ATHE
Alterity Therapeutics completes last patient visit in ATH434-201 trial
PremiumThe Fly
Alterity Therapeutics completes last patient visit in ATH434-201 trial
4M ago
ATHE
Alterity Therapeutics appoints Abby Macnish Niven as secretary
PremiumThe FlyAlterity Therapeutics appoints Abby Macnish Niven as secretary
5M ago
ATHE
Alterity Therapeutics announces presentation on bioMUSE study
Premium
The Fly
Alterity Therapeutics announces presentation on bioMUSE study
5M ago
ATHE
Alterity Therapeutics announces new publication on ATH434
Premium
The Fly
Alterity Therapeutics announces new publication on ATH434
5M ago
ATHE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >